Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis.
Tamás Fazekas, Sung Ryul Shim, Giuseppe Basile...
https://pubmed.ncbi.nlm.nih.gov/38576242/Actively Recruiting
Led by University of Chicago · Updated on 2026-03-02
250
Participants Needed
2
Research Sites
104 weeks
Total Duration
Researchers are investigating whether Magnetic Resonance Images MRI can detect high-grade prostate cancers earlier and more often in men who have a high risk of developing prostate cancer. The study focuses on men with different levels of genetic risk, including those with known gene mutations, high genetic risk scores, family history of prostate cancer, or low genetic risk. The research evaluates the role of MRI and genetic risk scores in screening men at elevated risk for prostate cancer. Participants will undergo MRI scans enhanced with gadolinium, an intravenous contrast agent used to improve imaging of the prostate. The study compares baseline prostate MRI results among men with various genetic risk factors and family histories to those without identifiable risk. The trial includes four groups based on germline mutations, genetic risk scores, family history, and low-risk status. During the study, participants will have prostate MRI scans every three years for up to 15 years. Researchers will monitor how often high-grade prostate cancer is detected through these screenings. The study team will also evaluate safety concerns related to gadolinium use and collect medical information related to prostate cancer diagnosis. Participation involves long-term follow-up with regular imaging to assess prostate health and cancer detection over time.
CONDITIONS
MRI Screening in Men at High Risk of Developing Prostate Cancer
S
Scott Eggener, MD
T
Teresa Barry
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Chicago
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | MRI‑based screening | PSA‑based screening |
|---|---|---|
| What it is | A screening pathway using prostate MRI applied by risk group assignment (germline mutation, high genetic risk score, family history, or low‑risk group) to detect high‑grade prostate cancer | Prostate‑specific antigen blood test used as the usual initial screening test |
| Role in trial | Investigational screening method evaluated for high‑grade cancer detection | Not evaluated in this trial but represents standard diagnostic approach |
| Primary use | Detect high‑grade prostate cancer in high‑risk individuals using imaging | Initial prostate cancer risk assessment using blood PSA level |
| How it is done | Men undergo prostate MRI stratified by risk categories | Blood draw for PSA level measurement |
| Evidence (broader) | Evidence is being developed; trial will assess detection rates of high‐grade cancer | PSA screening has demonstrated modest mortality benefit but with risk of overdiagnosis |
| Important risks | MRI may cause discomfort, is not suitable for individuals with metal fragments or severe claustrophobia | PSA test is minimally invasive but may lead to false positives and unnecessary biopsies |
| Important limitations | Not yet proven in reducing mortality or overdiagnosis; trial long‑term outcomes pending | PSA screening may detect indolent cancers and lead to overdiagnosis and overtreatment |
| Patient impact | Unknown until trial results provide evidence on cancer detection impact | Some mortality reduction demonstrated but balanced against harms from overdiagnosis |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 15 years
Participants undergo MRI screening to identify high-grade prostate cancers earlier and more frequently based on their risk group classification.
MRI screening every 3 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
FACTORIAL
Primary Purpose
SCREENING
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Tamás Fazekas, Sung Ryul Shim, Giuseppe Basile...
https://pubmed.ncbi.nlm.nih.gov/38576242/Jonas Hugosson, Rebecka Arnsrud Godtman, Jonas Wallstrom...
https://pubmed.ncbi.nlm.nih.gov/39321360/Lars Björnebo, Andrea Discacciati, Ugo Falagario...
https://pubmed.ncbi.nlm.nih.gov/38648061/University of Chicago
Lead Sponsor